## Data Sharing Statement

| Item | Question | Authors’ Response (place “-” if not applicable) |
|------|----------|-----------------------------------------------|
| 1    | Would you like to share data collected for your study to others? | Yes |
| 2    | If not, would you like to share the reason for your decision? | - |
| 3    | What data in particular will be shared? | The survival data and mutation abundance in particular will be shared. |
| 4    | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan and clinical study report will also be shared if requested. |
| 5    | When will data availability begin? | From the publication date. |
| 6    | When will data availability end? | Two years within the publication date, since the technique or survival date may be updated over time. |
| 7    | To whom will you share the data? | Medical oncologists who are interested in studies of targeted therapy. |
| 8    | For what type of analysis or purpose? | For analysis to evaluate the TKI efficacy and prognosis in NSCLC patients. |
| 9    | How or where can the data/documents be obtained? | The data are available from the corresponding author upon request by Email. |
| 10   | Any other restrictions? | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |

[Article Info](http://dx.doi.org/10.21037/atm-20-7155)